News release for PWRM, HNSN, and CLDA
Power3 Medical Products, Inc. (OTCBB: PWRM) and StemTroniX, Inc., a Texas corporation announced that a joint provisional patent application entitled, “Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy” has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office. The patent application covers the convergence of technologies at StemTroniX and Power3 in anticipation of the upcoming acquisition of StemTroniX by Power3. The provisional patent application discloses technologies designed to enhance the therapeutic process capabilities through the identification of the patients’ own stem cells. This patent application will be assigned by the inventors to the surviving public entity, to be named “StemTroniX,” upon the closing of the acquisition of StemTroniX by Power3.
PWRM is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.
For more information please visit www.power3medical.com
Hansen Medical, Inc. (NASDAQ:HNSN) announced the successful completion of a pre-clinical in-vivo study evaluating its new vascular robot, which demonstrated improvements in catheter navigation, reductions in vessel trauma during catheter manipulation, and improvements in access time for some vessels, as compared to manual catheter manipulation during endovascular procedures. Results also showed that the company’s vascular robot has the potential to standardize catheter navigation, which may lead to more predictable procedures. The early, but encouraging results were presented June 12, 2010 at the Society of Vascular Surgery’s 2010 Vascular Annual Meeting in Boston.
HNSN develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company’s robotic navigation system enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. Hansen Medical’s Sensei® system and its Sensei X Robotic Catheter System are compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. The remote navigation platform was cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures.
For more information please visit www.hansenmedical.com
Clinical Data, Inc. (NASDAQ: CLDA) announced the closing of its previously announced public offering of 2,237,412 newly issued shares of common stock, including 291,836 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters, at a price to the public of $14.30 per share. The shares offered by Clinical Data, Inc. exhausted all remaining shares on its existing shelf registration statement. The net proceeds from the sale of the shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million.
CLDA develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in other major therapeutic areas. Clinical Data combines its drug development and biomarker expertise in an effort to develop products with enhanced efficacy and tolerability to improve patient health and reduce costs.
For more information please visit www.clda.com
Sign Up for our Free Stock Newsletter at http://www.pennyotcstock.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Our disclaimer (http://pennyotcstock.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
